Showing results (451-460 of 587) with videos related to
Sort By:
Pageof 59
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.Journal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.The Lancet. Oncology|April 11, 2014
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialJohn Primrose, Stephen Falk, Meg Finch-Jones, et al.Pageof 59